Stem-cell–made eye tissue transplant for dry macular degeneration
Part of Eyes & vision, Genetic & congenital clinical trials.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with dry age-related macular degeneration (AMD), not the wet type
- You’re able to understand the study and sign informed consent
- You’re 55 years or older
- You’re medically able to have eye surgery (vitrectomy) and a shot into the space under the retina
- If you’re female, you are past menopause (or, if applicable, your partner situation allows pregnancy prevention per the study)
- If you’re male, you agree to use barrier contraception plus sperm-killing protection during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
This trial tests if a treatment made from umbilical cord blood and platelet-rich plasma can help people with dry age-related macular degeneration. The treatment is given as an injection into the eye, and the goal is to see if it slows vision loss or improves sight.
This trial tests whether injections made from umbilical cord blood “platelet-rich plasma” can improve vision in people with dry age-related macular degeneration (AMD) in both eyes. It targets older adults with specific vision levels and no major other eye or medical problems that could affect the results.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
Hear when a new Dry Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.